WestKam Gold Terminates Acquisition of McConnell Property in British Columbia
Vancouver, Canada, Jan. 05, 2024 (GLOBE NEWSWIRE) — WestKam Gold Corp. (TSX-V:WKG)(the “Company” or “WestKam”) wishes to advise that the […]
Stryker to announce financial results for its fourth quarter and full year 2023
Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter […]
Constellation Brands Reports Third Quarter Fiscal 2024 Financial Results
VICTOR, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, reported today […]
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the […]
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need […]
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on […]
RCLCO Ranks Summerlin® and Bridgeland® Among Nation’s Top Five Best-Selling Master Planned Communities of 2023
THE WOODLANDS, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) — Summerlin® and Bridgeland®, two of the award-winning communities in the Howard […]
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndrome Collaboration expands […]
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
Immunocore announces strategic priorities and pipeline expansion ahead of 42ndAnnual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK […]
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity – Associated Inflammation
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company […]
